SCHEMBL1642205

SCHEMBL1642205

O=C(O)CNC(=O)c1c(O)c(C(=O)NCc2ccc(Cl)c(Cl)c2)cn(C2CCCCC2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 6/20 0.52
HRH3 Q9Y5N1 3/20 0.45
HIF1A Q16665 2/20 0.43
EGLN1 Q9GZT9 7/20 0.42
EGLN2 Q96KS0 4/20 0.42
OGFOD1 Q8N543 1/20 0.42
HIF1AN Q9NWT6 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 3/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
USP2 O75604 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
BBOX1 O75936 1/20 0.39
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641480 1.00 EGLN3 (0.52) EGLN3HRH3HIF1AEGLN1EGLN2
SCHEMBL1641788 0.99 EGLN3 (0.52) EGLN3HRH3HIF1AEGLN1EGLN2
SCHEMBL1642313 0.86 EGLN3 (0.57) EGLN3HRH3HIF1AEGLN1EGLN2
SCHEMBL1641775 0.80 EGLN3 (0.81) EGLN3HIF1AEGLN1ALDH1A1MAPT
SCHEMBL1642076 0.79 HRH3 (0.51) HRH3KDM4EALDH1A1MAPTHPGD
SCHEMBL1641138 0.79 EGLN1 (0.50) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL1642747 0.79 EGLN1 (0.50) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL1642486 0.79 EGLN1 (0.47) EGLN3HIF1AEGLN1EGLN2OGFOD1
SCHEMBL1642791 0.79 EGLN1 (0.50) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL1642369 0.78 EGLN1 (0.47) EGLN3HIF1AEGLN1EGLN2OGFOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885HRH3 442/4885HIF1A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.